Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Inc. (PFE) is running an observational study called “BEVACIZUMAB BS Intravenous Infusion 100 mg, 400 mg [Pfizer] Post‑Marketing Database Study.” The goal is to track how safe its Bevacizumab biosimilar is in real‑world use for colorectal cancer patients in Japan and see how it compares with Avastin, a long‑time standard treatment.

The study looks at two drugs used in regular care, not in a trial clinic. One is Pfizer’s Bevacizumab‑Pfizer Biosimilar and the other is Roche’s Avastin. Both are antibody drugs designed to block blood vessel growth in tumors, and the focus here is on safety patterns rather than new dosing or new combinations.

The study is observational, so doctors do not assign treatment and there is no randomization. Instead, researchers use past hospital claims data to form two groups, one on Pfizer’s biosimilar and one on Avastin, and then compare outcomes over time in a retrospective cohort model.

The dataset covers patients treated between December 1, 2019, and November 30, 2024, so it spans several years of real‑world practice. The study was first submitted on April 7, 2026, with the latest update on May 20, 2026, showing the protocol is active and still recruiting data from the database.

For investors, this update supports Pfizer’s push in oncology biosimilars, a price‑sensitive and growing segment. Stable or better safety signals versus Avastin could strengthen PFE’s share in Japan and other markets, while any safety concern might slow uptake and favor incumbents like Roche or other biosimilar players.

The study remains ongoing and updated, with fuller technical details available on the ClinicalTrials.gov portal under the listed identifier.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.